BackSalarius Pharmaceuticals Overview

Salarius Pharmaceuticals Other Current Assets

Salarius Pharmaceuticals's other current assets is $540K.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$537044.00
5.99% YoYΔ $30338.00 vs prior year quarter

Peer average

Loading

Salarius Pharmaceuticals Other Current Assets History

Loading

Salarius Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Salarius Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Salarius Pharmaceuticals (SLRX) FAQ

Salarius Pharmaceuticals (SLRX) currently reports a other current assets of $540K as of March 2026. That compares with $510K in the prior-year period — up 6.0% year over year. Use the charts on this page to explore Salarius Pharmaceuticals's other current assets history and peer comparisons.

Salarius Pharmaceuticals's other current assets increased from $510K to $540K — a 6.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Salarius Pharmaceuticals reported $540K in other current assets as of March 2026. That compares with $510K in the prior-year period — up 6.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $540K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Salarius Pharmaceuticals, and consider following SLRX for alerts when major investors trade the stock.

Salarius Pharmaceuticals is classified in the Healthcare sector. On other current assets, it currently shows $540K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SLRX with unrelated industries.